Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019829 (
Hodgkin's disease
)
30,247
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Three human non-
Hodgkin
lymphomas of B-cell origin have been maintained as xenografts in artificially immunosuppressed mice. The long-term maintenance (3-5 years) resulted in no significant change in the morphology, DNA-index or cell surface markers of the tumors. Immunophenotyping revealed many similarities in the morphologically distinct lines. Light chain (lambda) restriction appeared in two lines (HT 58 and 130), but in the third line (HT 117) the co-expression of both light chains indicated the origin from light chain 'uncommitted' B cells. HT 117 was also different, expressing high
transferrin
-receptor activity, although it proliferates with practically the same rate as the other two lines. This study confirms the value of the xenograft system to approaching many tumor-specific problems.
...
PMID:Phenotypic characteristics of three human non-Hodgkin lymphoma lines: flow cytometric analysis after long-term maintenance. 322 46
The MLR-3 monoclonal antibody reacts with activated but not with resting lymphocytes. We report that MLR-3 identifies an early activation molecule since its binding is detectable on T cells 1.5-2 hr after in vitro activation. Its expression, therefore, does not require DNA synthesis and precedes, by many hours, that of the receptors for interleukin-2 (IL-2R) and
transferrin
(TF-R). The MLR-3 antigen is also found on activated thymocytes (including the large early thymic CD3- subset) and B cells. The majority of T- and B-lymphoblastoid cell lines, as well as the myeloid and erythroid cell lines HL60, GM1 and K562, are MLR-3+; conversely, non-haemopoietic cell lines are MLR-3 negative. Seventy percent of B-cell chronic lymphocytic leukaemia and 15% of B non-
Hodgkin
's lymphomas (B-NHL) are MLR-3+. On tissue sections MLR-3 is reactive with epithelia, sweat glands, hair follicles and Henle's loop but not with vessels, connective, endothelium and many other tissues. In vitro studies show that MLR-3 (1-100 micrograms/ml) significantly alters the thymidine uptake of mitogen-treated lymphocytes:augmentation is found when T and B cells are induced with TPA-Ionomycin and reduction when induced with phytohaemoagglutinin (PHA) or Staphylococcus aureus Cowan strain 1 (SAC), respectively. On SDS-PAGE, MLR-3 immunoprecipitates a disulphide-linked heterodimer of MW 29,000-35,000: both subunits are glycosylated, phosphorylated and exhibit a pI of 4.1 and 5.0, respectively. Our data, particularly the in vitro results, suggest that the MRL-3 molecule could have an important role in the early hours of activation for the progression of resting lymphocytes into mitosis.
...
PMID:Early lymphocyte activation molecule defined by the monoclonal antibody MLR-3: biochemical and functional studies. 326 71
The monoclonal antibody OKT9 was applied to cryostat sections of 267 non-
Hodgkin
's lymphomas and related neoplasms. It was found that the transferrin receptor is expressed by a wide variety of B- and T-lineage non-
Hodgkin
's lymphomas. The OKT9 staining also was loosely correlated with the three morphologic grades of non-
Hodgkin
's lymphomas identified by the International Working Formulation. In general, higher grade lymphomas more often and more intensely expressed the T9 antigen. However, transferrin receptor expression by certain histologic subtypes of lymphoma did not correlate with their morphologic grade: low-grade follicular lymphomas expressed the T9 antigen more frequently than diffuse low-grade lymphomas; diffuse small cleaved cell lymphomas were stained by OKT9 less often than other histologic subtypes of intermediate-grade lymphomas; and diffuse immunoblastic lymphomas expressed
transferrin
receptors less often than the other high-grade histologic subtypes of non-Hodgkin's lymphoma. Intermediate lymphocytic lymphomas, not recognized in the International Working Formulation, were infrequently and weakly stained by OKT9 in a manner similar to diffuse low-grade lymphomas. We obtained clinical follow-up data on 43 individuals with chronic lymphocytic leukemia/small lymphocytic lymphoma and 64 individuals with diffuse large cell and immunoblastic lymphoma. Transferrin receptor expression in these two groups did not correlate significantly with survival.
...
PMID:Transferrin receptor expression by non-Hodgkin's lymphomas. Correlation with morphologic grade and survival. 335 78
Severe impairment of the lymphopoietic cell renewal system is an important etiological factor of cancer development and it may be the consequence of massive radio and/or chemotherapeutic regimens. In a comparative study, we analysed the potential, systemic immunorestoratory capacity of bestatin, a microbial leucil-aminopeptidase inhibitor and of the ubiquitous trace element zinc. In vivo administration of bestatin in mice stimulated both Interleukin 1 and Interleukin 2 production, and enhanced T cell, B cell as well as macrophage mediated immunoreactions. In a phase II clinical trial on 41 patients with non-
Hodgkin lymphoma
,
Hodgkin disease
and solid tumors, bestatin treatment corrected the pathological frequency of both OKT4 and OKT8 lymphocyte subpopulations. Zinc-saturated
transferrin
had a significative stimulatory effect on the ongoing DNA synthesis of antigen activated human lymphocytes in culture. Oral administration of zinc-gluconate to patients who manifested a severe T cell subpopulation defect corrected preferentially the OKT8 suppressor/cytotoxic T cell unbalances. The clinical results obtained by both bestatin and zinc were observed only on a short-term, so further studies are needed to elaborate long lasting regiments and to establish whether these treatments have determinant influence on the underlying disease.
...
PMID:From experimental to clinical attempts in immunorestoration with bestatin and zinc. 353 99
The distribution of iron and iron binding proteins (IBP) have been compared with control spleen tissue in an attempt to establish a pattern of staining restricted to
Hodgkin's disease
(HD). All but one of the HD spleens examined stained for ferritin, which was largely present in red pulp dendritic macrophages (DM). In spleens histologically involved with HD heavy deposits of ferritin were seen around tumour nodules. Staining for ferritin increased with involvement of the spleen in HD but DM still represented the bulk of positive cells. However, ferritin positive DM were frequently seen in control spleens, and often in large numbers. Staining of ferric iron by Perls technique was less prominent than ferritin but this observation was also true of the non-HD spleens studied. Patterns of staining with
transferrin
were equivalent in both groups of spleens with DM being the most frequently positive cell type. Polymorphous macrophages showing erythrophagocytosis were present in the red pulp sinuses of all groups of spleens and although these cells have been considered as precursors of the Reed-Sternberg cell their presence seemed related to total splenic ferritin regardless of the disease process. These cells marked as macrophages and their presence was not restricted to HD. The results show that there is no particular appearance of iron or IBP distribution which is restricted to HD spleens. However, staining for ferritin and iron increased in HD spleens with tumour involvement and could contribute to circulatory abnormalities in this disease.
...
PMID:The distribution of iron and iron binding proteins in spleen with reference to Hodgkin's disease. 374 63
The haemoglobin, serum iron,
transferrin
saturation, serum ferritin, erythrocyte sedimentation rate (ESR), splenic weight and non-haem iron concentration in the marrow, liver and spleen were measured prior to treatment in 35 patients with
Hodgkin's disease
who underwent staging laparatomy. The Hb, serum iron and
transferrin
saturation showed a significant decrease with increasing stage of the disease. In contrast, there was a significant increase in the serum ferritin, ESR, splenic weight and in all the tissue non-haem iron concentrations. The calculated total iron content of the body remained relatively constant throughout at about 2 g but with increasing stage there was an internal redistribution of iron, with a progressive drop in Hb iron and a reciprocal rise in storage iron, especially in the liver. Serum ferritin concentrations, which rose with progression of the disease, were inappropriately high in relation to the size of body stores at all stages but especially in patients with 4B disease and hepatic involvement. It was concluded that the serum ferritin concentrations are raised for several reasons in
Hodgkin's disease
. They reflect an increase in body iron stores, ferritin's role as an 'acute phase' protein in the inflammatory response and hepatic damage in patients with advanced disease.
...
PMID:Serum ferritin and Hodgkin's disease. 408 30
The serum ferritin concentration is increased in both acute myeloblastic leukaemia and
Hodgkin's disease
. In acute leukaemia the mean concentration is about ten times the normal level and is associated with a high concentration of
transferrin
-bound iron. In
Hodgkin's disease
abnormal ferritinaemia is associated with a low concentration of
transferrin
-bound iron and appears to result from a block of reticuloendothelial iron release. Increased concentrations of circulating ferritin have also been observed in a few cases of chronic leukaemia and myelomatosis.
...
PMID:Ferritinaemia in leukaemia and Hodgkin's disease. 451 89
Lyophilized frozen sections of 24 lymph nodes from patients with different types of non-
Hodgkin
's malignant lymphoma, diagnosed according to the Kiel Classification, were tested by an immunoperoxidase-ABC-method, in order to assess the expression of the
transferrin
receptors, recognized by the OKT9 monoclonal antibody. Our results support the hypothesis that OKT9 reactivity of lymphomatous tissues might reflect the histological grading, offering a new important prognostic parameter, and stress the concept that immunological studies in frozen sections allow a more precise definition of the lymphoma phenotype.
...
PMID:Immunohistological study of transferrin receptor expression in non-Hodgkin's lymphoma. 609 47
The proportion of lymphocytes from patients with non-
Hodgkin lymphoma
(NHL) expressing
transferrin
receptors in biopsy material from lymph-nodes assayed by binding of the monoclonal antibody OKT9 correlated significantly with the histological class of the tumour. High-grade lymphomas contained 22.5% (range 3-57%) OKT9-positive lymphocytes, and low-grade lymphomas contained 2.5% (range less than 1-22). Since histological class of lymphoma is an important factor in survival, it was expected and confirmed that OKT9 levels were related to survival in these patients. Transferrin receptor is expressed by growing cells. The correlates observed in this series of NHL suggests a relation between transferrin receptor and either the growth fraction, or factors affecting the growth fraction, of the tumour.
...
PMID:Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. 613 Dec 11
The distribution of
transferrin
receptors (TR) has been studied in a range of normal and malignant tissues using four monoclonal antibodies, BK19.9, B3/25, T56/14 and T58/1. In normal tissues TR was found in a limited number of sites, notably basal epidermis, the endocrine pancreas, hepatocytes, Kupffer cells, testis and pituitary. This restricted pattern of distribution may be relevant to the characteristic pattern of iron deposition in primary haemachromatosis. In contrast to this limited pattern of expression in normal tissue, the receptor was widely distributed in carcinomas, sarcomas and in samples from cases of
Hodgkin's disease
. This malignancy-associated expression of the receptor may play a role in the anaemia of advanced malignancy by competing with the bone marrow for serum iron.
...
PMID:Transferrin receptors in human tissues: their distribution and possible clinical relevance. 630 35
<< Previous
1
2
3
4
Next >>